UY33392A - Lactamas sustituidas con piperidinilo como moduladores de gpr119 - Google Patents

Lactamas sustituidas con piperidinilo como moduladores de gpr119

Info

Publication number
UY33392A
UY33392A UY0001033392A UY33392A UY33392A UY 33392 A UY33392 A UY 33392A UY 0001033392 A UY0001033392 A UY 0001033392A UY 33392 A UY33392 A UY 33392A UY 33392 A UY33392 A UY 33392A
Authority
UY
Uruguay
Prior art keywords
gpr119
modulators
readers
piperidinyl
replaced
Prior art date
Application number
UY0001033392A
Other languages
English (en)
Inventor
Thomas Daniel Aicher
Josef Roland Bencsik
Steven Armen Boyd
Kevin Ronald Condroski
Bradford Jay
John P Fischer
Ronald Jay Hinklin
Scott Alan Pratt
Singh Ajay
Timothy M Turner
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY33392A publication Critical patent/UY33392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compuestos de la Fórmula I y sales farmacéuticamente de ellos, en donde X 1 , X2 , L, R3 , R4 ,R5 , R6 , R6a , R7 , R9 , R9a , y n tienen las definiciones que se dieron en la memoria descriptiva, son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetes, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas .
UY0001033392A 2010-05-17 2011-05-17 Lactamas sustituidas con piperidinilo como moduladores de gpr119 UY33392A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34546110P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
UY33392A true UY33392A (es) 2012-11-30

Family

ID=44584599

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033392A UY33392A (es) 2010-05-17 2011-05-17 Lactamas sustituidas con piperidinilo como moduladores de gpr119

Country Status (20)

Country Link
US (1) US8754226B2 (es)
EP (1) EP2571864A1 (es)
JP (1) JP2013530947A (es)
KR (1) KR20130113948A (es)
CN (1) CN103080101A (es)
AR (1) AR081197A1 (es)
AU (1) AU2011256455A1 (es)
BR (1) BR112012029395A2 (es)
CA (1) CA2799779A1 (es)
CL (1) CL2012003211A1 (es)
CO (1) CO6670520A2 (es)
CR (1) CR20120642A (es)
IL (1) IL223092A0 (es)
MX (1) MX2012013465A (es)
RU (1) RU2012154308A (es)
SG (1) SG185615A1 (es)
TW (1) TW201141849A (es)
UY (1) UY33392A (es)
WO (1) WO2011146335A1 (es)
ZA (1) ZA201209605B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
KR101415742B1 (ko) * 2011-12-21 2014-07-04 영남대학교 산학협력단 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AU2015239020A1 (en) * 2014-04-04 2016-10-13 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CN107207268A (zh) 2015-01-19 2017-09-26 福吉米株式会社 改性胶体二氧化硅及其制造方法、以及使用其的研磨剂
KR102604533B1 (ko) 2015-01-19 2023-11-22 가부시키가이샤 후지미인코퍼레이티드 연마용 조성물
CN108368099B (zh) 2015-12-17 2021-11-12 先正达参股股份有限公司 杀微生物的噁二唑衍生物
US10392366B2 (en) 2017-02-21 2019-08-27 Sanofi Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
MX2022016455A (es) 2020-06-22 2023-02-01 Hoffmann La Roche Derivados de sulfona.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
BRPI0507971A (pt) 2004-02-23 2007-07-24 Tufts College composto, composição farmacêutica, uso de um composto,método para inibir a atividade proteolìtica de uma enzima de clivagem pós-prolina e remédio empacotado
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
DK1756084T3 (da) 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
CA2586883A1 (en) * 2004-11-22 2006-06-01 Merck & Co., Inc. Piperidinyl piperidine tachykinin receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
KR20080025190A (ko) 2005-06-30 2008-03-19 프로시디온 리미티드 Ｇ-단백질 결합된 수용체 효능제
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
US20080025795A1 (en) * 2006-07-28 2008-01-31 Cliff Purnell Methods, apparatus and system for drain tiles
JP2010501629A (ja) * 2006-08-30 2010-01-21 ビオヴィトルム・アクチボラゲット（プブリクト） Ｇｐｒ１１９関連障害を治療するためのピリジン化合物
AU2007342531B2 (en) 2006-12-20 2011-10-13 Merck Sharp & Dohme Corp. Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、***和四唑衍生物
EP2321308B9 (en) 2008-07-10 2012-08-08 Prosidion Limited Piperidine gpcr agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CA3082212C (en) * 2009-09-04 2023-03-07 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
KR20130099970A (ko) 2010-09-17 2013-09-06 어레이 바이오파마 인크. Gpr119 조절제로서의 피페리디닐-치환된 락탐류
US20140256756A1 (en) 2011-11-03 2014-09-11 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2013074641A1 (en) 2011-11-16 2013-05-23 Array Biopharma Inc. Piperidinyl- substituted cyclic ureas as gpr119 modulators

Also Published As

Publication number Publication date
MX2012013465A (es) 2013-12-02
US8754226B2 (en) 2014-06-17
SG185615A1 (en) 2012-12-28
US20130158009A1 (en) 2013-06-20
AR081197A1 (es) 2012-07-04
EP2571864A1 (en) 2013-03-27
JP2013530947A (ja) 2013-08-01
CL2012003211A1 (es) 2013-04-26
AU2011256455A1 (en) 2013-01-10
TW201141849A (en) 2011-12-01
IL223092A0 (en) 2013-02-03
CR20120642A (es) 2013-03-11
ZA201209605B (en) 2014-05-28
WO2011146335A1 (en) 2011-11-24
CO6670520A2 (es) 2013-05-15
BR112012029395A2 (pt) 2016-07-26
CA2799779A1 (en) 2011-11-24
CN103080101A (zh) 2013-05-01
KR20130113948A (ko) 2013-10-16
RU2012154308A (ru) 2014-06-27

Similar Documents

Publication Publication Date Title
UY33392A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119
UY33614A (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
BR112013002957A2 (pt) composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
EA201590296A1 (ru) Дейтерированный ибрутиниб
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
AR077642A1 (es) Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
BR112012030482A2 (pt) tratamento de diabetes tipo 2
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CO6491033A2 (es) 5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
BR112012028906A2 (pt) polimorfos de benzoato de alogliptina
ES2658818T3 (es) Compuestos del complejo FE(III) para el tratamiento y la profilaxis de síntomas asociados a deficiencia de hierro y de anemias ferropénicas
FR2974364B1 (fr) Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique
CO6700858A2 (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
UY34120A (es) Combinación sinérgica para el tratamiento de diabetes mellitus tipo 2
TH119596B (th) ลวดลายจาน

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200629